DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Exclusion Criteria

• •1. Any unresolved \> Grade 1 adverse event at the time of starting study treatment with the exception of alopecia.
• •2. Prior history of allogeneic hematopoietic stem cell transplantation
• •3. Stem cell transplantation, cell therapy, or gene therapy within 90 days. Approved small molecule therapy within 5 half-lives, investigational small molecule therapy within 14 days. Monoclonal antibodies and antibody-drug conjugates within 28 days Radiation therapy within 1 weeks
• •4. Live attenuated vaccines or viral vector vaccines within 4 weeks. Major surgery or significant traumatic injury within 4 weeks. History of stroke or intracranial hemorrhage within 6 months
• •5. Participants with non-CNSL presence of CNS or intraocular lymphoma lesions.
• •6. CNSL participants with systemic presence of lymphoma, unable to complete lumbar puncture, under systemic corticosteroids at a dose \> 8 mg/day (dexamethasone equivalent dose) within 14 days or requiring immunosuppressive or biologic therapy."
• •7. Participants with infectious disease:
• •8. Clinically significant cardiac disorders or abnormalities
• •9. Another malignancy within 5 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or non-melanomatous skin cancer.
• •10. Refractory nausea and vomiting if not controlled by supportive therapy, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption
• •11. Women who are breast feeding
• •12. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol